Business Wire

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Share

Celltrion Group today announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralising potency against emerging virus mutations and that the company has initiated development of a neutralising antibody cocktail treatment with CT-P59.

The Korea Disease Control and Prevention Agency (KDCA) has assessed and independently confirmed that CT-P59 successfully neutralises the SARS-CoV-2 variants first identified in the UK (B.1.1.7) in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S·L·V·G·GH·GR). They also added that cocktail therapy of CT-P59 with another monoclonal antibody candidate demonstrated neutralising capability against the UK (B.1.1.7) and South African (B.1.351) variants.

As of 19 January 2021, according to media and official sources, approximately 2,000 cases of the variant VOC 202012/01 (Variant of Concern, year 2020, month 12, variant 01, previously designated VUI, Variant under Investigation) had been identified in 60 countries. In the EU/EEA, about 1,300 cases have been identified in 23 countries. Outside the EU/EEA, approximately 700 cases have been identified in 37 countries.1

In order to elicit potent neutralising antibodies against the new emerging variants and to minimise lead time for introducing cocktail treatments with CT-P59, Celltrion previously captured a total of 38 potent neutralising antibodies against SARS-CoV-2 in which antibody candidate No. 32 produced neutralising titres against new emerging strains in the UK and South Africa. Using an already constructed antibody portfolio and encouraged by confirmed potency on various mutants, Celltrion has commenced the development of a neutralising antibody cocktail with CT-P59 against new emerging variants of SARS-CoV-2.

To date, CT-P59 has been shown to significantly reduce the risk of COVID-19 related hospitalisation and oxygenation up to Day 28, reduce rate of progression to severe COVID-19 by 54% for patients with mild-to-moderate symptoms and 68% for moderate patients aged 50 years and over, and significantly shorten the time to clinical recovery ranging from 3.4 to 6.4 days quicker compared to placebo. A global Phase III clinical trial is currently recruiting and is expected to enroll 1,172 patients with mild-to-moderate symptoms of COVID-19 at more than 10 global sites to evaluate the efficacy and safety of CT-P59.

Global Principal Investigator Professor Adrian Streinu-Cercel, MD, PhD, Professor of Infectious Diseases at the Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, said, “CT-P59 has demonstrated its ability to shorten time to clinical recovery and reduce rate of progression to severe COVID-19. From the clinical trial, one of my patients with COVID-19 aged 85 and with an underlying condition, has recovered from the virus within 48 hours of being treated with CT-P59. The antibody treatment candidate would be most useful within 3-5 days of testing positive for the virus. This will greatly aid efforts to address the current burden on healthcare systems and resources.”

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.

About CT-P59 (Regdanvimab)

CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. The mutated G-variant strain (D614G variant) was later identified and confirmed to be inactivated by CT-P59. In pre-clinical data the treatment candidate demonstrated a 100-fold reduction in viral load of SARS-CoV-2, as well as a reduction in lung inflammation. Results from the global Phase I clinical trial of CT-P59 demonstrated promising safety, tolerability, antiviral effect and efficacy profile in patients with mild symptoms of COVID-19.2

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.

These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

References


1 Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update 21 January 2021, European Center for Disease Prevention and Control. [Last accessed February 2021]

2 Celltrion Data on file

Contact information

Holly Barber
hbarber@hanovercomms.com
+44 (0) 07759 301620

Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

World Government Summit “21 Dialogues” to Deliver 21 Post-Pandemic Predictions8.3.2021 13:22:00 CETPress release

The World Government Summit Dialogues will deliver 21 predictions for the future social, economic, and political order, between 9 – 10 March. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005451/en/ The World Government Summit Dialogues convenes world leaders for two days of virtual sessions to forecast the future trends that will shape the world (Photo: AETOSWire) The virtual event will host political and industry leaders from around the world, who will each offer their outlooks on the future of vital sectors including healthcare, space, cryptocurrency and more. Day one will open with a keynote from His Excellency Mohammad Abdullah Al Gergawi, the UAE’s Minister of Cabinet Affairs and Chairman of the World Government Summit Organization, on the priorities for governments in 2021, as they look to navigate the global recovery from the coronavirus (COVID-19) pandemic. Sessions on day one will focus on the future of Afri

Global Blue Acquires ZigZag Global, a Leading E-commerce Returns Platform8.3.2021 13:01:00 CETPress release

Global Blue today announced the acquisition of ZigZag, a leading Software-as-a-Service (SaaS) technology platform that helps retailers manage worldwide e-commerce returns and exchanges more profitably, and consumers to enjoy a smoother and enhanced return experience. ZigZag enables merchants to optimise their e-commerce growth E-commerce returns are a big problem for retailers with more than 40% of orders on average being returned. ZigZag’s technology platform addresses this issue by digitalising the e-commerce returns process and improving the returns experience for both consumers and retailers. It replaces outdated paper-based “label in the box” solutions with a best in class online returns portal that offers a greater range of shipping options including post office, parcel shops, lockers and collection from home, as well as exchange alternatives. In parallel, it optimises retailers’ profitability by reducing logistical costs via consolidation, local market resale, and inbound consum

IFF Announces Agreement With Sachem Head8.3.2021 12:55:00 CETPress release

IFF (NYSE: IFF) today announced that it has reached an agreement with Sachem Head Capital Management LP (“Sachem Head”), under which Sachem Head will have the option for Managing Partner Scott Ferguson to join IFF’s Board of Directors between September 10, 2021 and December 31, 2021. Should Sachem Head choose to have Mr. Ferguson join the IFF Board, the Board would expand from 13 to 14 directors. “We have engaged in constructive conversations with Sachem Head around our plans to achieve the full potential of our combination with DuPont’s N&B business for the benefit of all shareholders,” said IFF Chairman and Chief Executive Officer, Andreas Fibig. “This agreement reflects our commitment to continued shareholder engagement and long-term value creation as well as to ensuring we achieve the substantial cost and revenue synergies that we have identified in connection with the N&B transaction.” Scott Ferguson, Managing Partner of Sachem Head, said, “The recent actions taken by IFF undersco

Velodyne Lidar Announces Executive Appointments to Advance Company’s Continued Global Lidar Market Leadership8.3.2021 12:48:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced that it has appointed Sinclair Vass as Chief Commercial Officer, succeeding Mike Jellen. Mr. Vass joins Velodyne from Focuslight Technologies, where he served as Corporate Senior Vice President and was responsible for driving profitable growth as the leader of its Laser Optics Business Unit. As Chief Commercial Officer of Velodyne Lidar, Mr. Vass will be responsible for worldwide sales and deepening the Company’s customer relationships. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005136/en/ Sinclair Vass, Chief Commercial Officer, Velodyne Lidar, Inc. (Photo: Velodyne Lidar, Inc.) In conjunction with Mr. Vass’s appointment, Mr. Jellen has been promoted to Chief Strategy Officer, where he will be responsible for advancing Velodyne’s growth through mergers and acquisitions and corporate development initiatives. Both Mr. Vass and Mr. Jellen will report directly

CLERHP Estructuras Signs a 10,000,000 Euros Equity Commitment With LDA CAPITAL8.3.2021 11:22:00 CETPress release

CLERHP Estructuras, an Engineering and Construction company based in Murcia (Spain) and listed on the BME GROWTH, has signed a 10 million euros equity commitment with the global alternative investment firm LDA Capital. The Company, with subsidiary companies in Bolivia, Paraguay, and Uruguay, is developing a new software for the AECO sector. CLERHP provides solutions for the optimization of building structures and new applications in the Virtual and Augmented Reality (AR) space for on-site productivity solutions. Juan Andrés Romero, president and CEO of the group stated: “The support of LDA Capital with the 10 million euros equity commitment guarantees our strong growth and will accelerate our digital projects”. Warren Baker, Managing Partner of LDA Capital, commented, “The time has come for the architecture, engineering, construction and owner (AECO) industry to adopt new technologies. As the industry looks to leverage new technology infrastructure to vastly improve the efficiency of p

Laura Schwarz Moves Up at Airship8.3.2021 10:00:00 CETPress release

The customer engagement platform for major brands Airship, wants to further expand its market leadership in the EMEA region and continue to grow both in market share and awareness. In order to consistently pursue this goal, the company is placing sales responsibility in this region in the hands of Laura Schwarz, who previously demonstrated her expertise as Airship’s Country Manager for Central and Eastern Europe, where she was responsible for new business in this region, among other things. The Munich based sales leader, will be heading the entire sales team across Europe, with the goal to support more European app owners in optimising their mobile marketing strategies. Schwarz, who speaks several languages, looks back on a varied career with different stations. After studying International Management in Heidelberg, she first founded her own company at the age of 22. She worked for the agencies Havas and pilot before discovering SaaS tech sales for herself and developing the DACH marke

Sabio Group Acquires makepositive, Expanding Focus on Customer Relationship Management8.3.2021 10:00:00 CETPress release

Sabio Group, a leading European full service CX provider, has acquired makepositive, a large UK-based independent Salesforce consulting partner. makepositive will strengthen Sabio’s ability to support customers with transformative cutting-edge CX technologies, particularly addressing the Human Service aspect of the CRM Customer Engagement Centre. Founded in 2003, makepositive is a multi-award-winning Salesforce consulting partner, with circa 180 employees, offices in London and Manchester, and a development centre in India. makepositive has over 120 Salesforce-accredited consultants with 700+ Salesforce certifications amongst them, as well as its own dedicated managed services capability. The company has delivered Salesforce projects for leading organisations, including Allocate, Aston Martin, Fujifilm, Gamma, McCarthy & Stone, Sohonet, Visioncall and Wolseley. “With AI and conversational technologies now handling many routine CX enquiries, contact centre advisors handle a greater prop